Treatment approaches for diabetes and dyslipidemia

Mingyuan Wu, Timothy J Lyons

Research output: Contribution to journalArticle

8 Citations (Scopus)


Dyslipidemia is an important risk factor for cardiovascular complications in persons with diabetes. Low-density lipoprotein-cholesterol (LDL-C) is the 'cornerstone' for assessment of lipoprotein-associated risk. However, LDL-C levels do not reflect the classic 'diabetic dyslipidemia' of hypertriglyceridemia and low high-density lipoprotein-cholesterol (HDL-C). Measurements of plasma apolipoprotein B100 concentrations and non-HDL-C may improve the definition of dyslipidemia. Statins, nicotinic acid and fibrates have roles in treating dyslipidemia in diabetes. Residual risk (i.e. risk that persists after correction of 'conventional' plasma lipoprotein abnormalities) is a new concept in the role of dyslipidemia in the pathogenesis of diabetic vascular complications. For example, regardless of plasma levels, lipoprotein extravasation through a leaking retinal blood barrier and subsequent modification may be crucial in the development of diabetic retinopathy. The current approach to the management of dyslipidemia in diabetes is briefly summarized, followed by a discussion of new concepts of residual risk and emerging lipoprotein-related mechanisms for vascular disease in diabetes.
Original languageEnglish
Pages (from-to)76-80
Number of pages5
JournalHormone research in pædiatrics
Volume76 Suppl 1
Publication statusPublished - 2011

Bibliographical note

Copyright © 2011 S. Karger AG, Basel.


  • Apolipoprotein B-100
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Diabetes Complications
  • Diabetes Mellitus
  • Diabetic Angiopathies
  • Diabetic Retinopathy
  • Dyslipidemias
  • Fibric Acids
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypolipidemic Agents
  • Niacin
  • Risk

Fingerprint Dive into the research topics of 'Treatment approaches for diabetes and dyslipidemia'. Together they form a unique fingerprint.

  • Cite this